• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640408)   Today's Articles (203)   Subscriber (50362)
For: Faber MG, Wang C, Kommi Reddy S, Meagher A, Early A, Chen H, Dy GK. Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience. Lung Cancer 2022;165:49-53. [PMID: 35085984 DOI: 10.1016/j.lungcan.2022.01.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Revised: 01/11/2022] [Accepted: 01/15/2022] [Indexed: 10/19/2022]
Number Cited by Other Article(s)
1
Lin X, Zhou W, Liu Z, Cao W, Lin C. Targeting cellular metabolism in head and neck cancer precision medicine era: A promising strategy to overcome therapy resistance. Oral Dis 2023;29:3101-3120. [PMID: 36263514 DOI: 10.1111/odi.14411] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/17/2022] [Accepted: 10/14/2022] [Indexed: 11/30/2022]
2
Cao P, Guo W, Wang J, Wu S, Huang Y, Wang Y, Liu Y, Zhang Y. Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients. Front Pharmacol 2022;13:954242. [PMID: 36105185 PMCID: PMC9466465 DOI: 10.3389/fphar.2022.954242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Accepted: 07/29/2022] [Indexed: 11/13/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA